Following a period of critical illness, physical function and health-related quality of life are slow to recover, both in the short and long term. Muscle wasting and weakness during the intensive care unit (ICU) admission is a recognised contributory factor. Enhanced rehabilitation programmes are advocated to improve outcomes, and electrical muscle stimulation (EMS) has been recommended during the early critical illness trajectory. This technique is fairly new to the ICU, and limited efficacy data exists for its use in this setting. This integrative review will examine published and on-going ICU studies with the purpose of reporting on the characteristics of EMS study participants; content of EMS treatment protocols; safety of EMS in the ICU setting; effects on EMS on muscle wasting; effects of EMS on muscle strength; and future research.
Introduction
Critical illness requiring prolonged periods of mechanical ventilation (MV) is often accompanied by skeletal muscle wasting and weakness, referred to as intensive care unitacquired muscle weakness (ICU-AW). This has a long-term legacy of reduced muscle force and endurance. 1 Subsequently, impaired functional ability and failure to return to pre-morbid physical status negatively impacts life quality, in some cases up to five years after initial illness. 2 Depending upon defining criteria, ICU-AW affects between 20-75% of patients ventilated for more than seven days 3, 4 and presents at awakening as reduced bilateral, symmetrical limb muscle power. Risk factors for developing ICU-AW, beyond the use of corticosteroids, immobility and hyperglycaemia, include the extent of organ failure, severity and duration of systemic inflammatory response, and the length of ICU stay. 5 Adjunctive to ICU-AW, respiratory muscle weakness is common and can prolong the duration of MV. 6 Increasingly recognised as a muscle dysfunction concomitant to muscle wasting, 7 atrophy starts rapidly after onset of MV and may be profound, with mass losses of up to 20% over the first week of ICU stay. 8 Early prevention of ICU-AW is a challenge and although implementing progressive mobilisation programmes can improve short-term functional outcomes, 9 continuing sedation and clinical instability may delay the start of aerobic activity for a proportion of patients. Treatment options during this prolonged immobilisation period are limited to passive movements which, although recommended, 10 are inconsistently delivered. 11, 12 Electrical muscle stimulation (EMS), an electrotherapy modality widely used by physiotherapists, has featured recently in the literature. It consists of a portable pre-programmed EMS unit with attaching surface electrodes placed over superficial muscles, and between which a current flow is formed. This propagates action potentials from intramuscular motor nerves, inducing repetitive isometric muscle contractions. 13 Evoking minimal joint movement, these are suitable for the recumbent, immobile patient. EMS is advantageous in that it is independent of patient interaction and may be administered soon after ICU admission. It therefore has the potential to bridge the gap between immobility and the onset of more active exercise.
There is a wealth of evidence in healthy subjects and patients with impaired motor function that regularly exercising muscles with EMS can preserve and restore mass during periods of immobilisation or disuse, 14 and improve muscle strength, 13, 15 changes that can translate into functional exercise capacity benefits. 16, 17 EMS has recently been incorporated in ICU rehabilitation guidelines 10 although evidence for its use in this population is thus far equivocal and the technique is not widely used.
Purpose of the review
Published EMS studies in ICU settings are limited and thus considered insufficient for meta-analysis or systematic review. An integrative review, permitting the review of all trial designs and protocols of on-going studies on clinical trial registers, was therefore chosen. The purpose of this is to report: 1. Characteristics of EMS study participants 2. Content of EMS treatment protocols 3. Safety of EMS in ICU settings 4. Effects of EMS on muscle wasting 5. Effects of EMS on muscle strength 6. Future research.
BUSINESS ELITE databases using the key words; 'electrical muscle stimulation,' 'transcutaneous electrical stimulation,' 'neuromuscular electrical stimulation,' 'intensive care,' 'critical care,' 'ICU,' 'ITU,' 'critical illness' and 'critically ill.' All databases were searched from start to January 2013 and resourced studies and reviews were hand-searched for additional relevant articles. Due to the recent implementation of EMS, ICU-based studies of any methodological design were included. Studies published in abstract and those in non-English language were excluded. Clinical trial registers ClinicalTrials.gov, 18 Current Controlled Trials 19 and Australian New Zealand Clinical Trials Register 20 were also searched. Studies not investigating EMS as a primary research comparator were excluded.
Results
The database search identified 77 unique publications: 55 unrelated articles, two non-English reviews of EMS in ICU, two author notes, and nine abstracts were excluded. The remaining nine clinical studies were included for review: six randomised, controlled trials (RCTs), 8, [21] [22] [23] [24] [25] one exploratory trial, 26 one crossover trial, 27 and one protocol. 28 Hand-searching identified one post hoc analysis report 29 and one protocol, 30 and three additional protocols were identified on clinical trial registers. [31] [32] [33] In total, 11 publications and three trial register protocols were included in the review (Figure 1 and Table 1 ).
Characteristics of EMS study participants
All eight completed EMS studies were set in European ICUs and selected critically ill patients based on single or combined risk factors for development of ICU-AW: expected duration of MV and sedation; respiratory failure with single or multi-organ failure; and illness severity. Potentially confounding risk factors were detailed by four studies, patients receiving neuromuscular blocking agents were excluded from one study, 25 four cohorts included a subgroup receiving corticosteroids 8, 21, 23, 25 and three studies detailed glycaemic control measures. 8, 21, 25 Five studies stipulated body mass index eligibility restrictions, as well as known EMS contraindication exclusions. 8, [21] [22] [23] 26 Only one post hoc analysis 29 of an earlier RCT 23 detailed participant premorbid chronic disease status (and thus potential pre-existing myopathy), and all but three studies 21,23,26 treated on average, older patients (mean age ≥61 years). Groups within studies were generally well matched for demographic characteristics.
Participants were recruited immediately after ICU admission to the six RCTs, with a total of 286 patients generating 152 evaluable datasets. 8, [21] [22] [23] [24] [25] Attrition was consistent with accepted ICU mortality rates, although two studies lost around a quarter of primary outcome data due to limb oedema obscuring ultrasound images, 21 and inadequate cognitive ability precluding strength assessment. 23 Two study cohorts recruited medical and surgical patients with admission APACHE scores <20 21,23 and two cohorts 8, 25 exclusively recruited septic patients with median APACHE scores of 20 and 25 respectively. All RCTs commenced EMS within three days of ICU admission, with a subgroup of patients receiving treatment after a mean of 33 (±15) days. 22 Overall, apart from the homogeneous septic and cardiac surgery cohorts, 8, 24, 25 study participants represented a fairly typical heterogeneous mix of medical and surgical ICU patients.
Content of EMS treatment protocols
Despite a wide body of evidence demonstrating EMS efficacy in improving muscle strength and preventing atrophy outside the ICU, there is considerable heterogeneity between protocols and limited consensus on the optimal current and contraction characteristics. 13 This is mirrored in ICU studies. The majority delivered single daily 60 minute EMS treatments, with only two studies treating for 30 minutes twice daily. 25, 27 All targeted the quadriceps femoris muscle in isolation 8, 22, 24 or in combination with peroneus longus 21, 23 or biceps. 25 Although the rationale for choice of the latter two muscles is unclear, the quadriceps is a functionally important anti-gravity muscle group which atrophies quickly upon immobilisation and is the most frequently stimulated in clinical EMS studies. Importantly, the impaired quadriceps is amenable to architectural change with stimulation 35 and evoked muscle force changes can translate into clinically significant improvements in exercise capacity. 16, 17 EMS parameters can markedly influence neuromuscular adaptations, but the main considerations for choosing settings are early onset fatigue and pain. Wide pulsed, high frequency EMS is recommended for evoking changes in muscle force in healthy and impaired muscle, 34 although high frequency current is more uncomfortable, potentially more damaging 36 and debatably preferentially stimulates fast muscle fibres 37 inducing earlier onset of fatigue. In keeping with this, only one ICU study employed high frequency stimulation. 24 The intensity of EMS indirectly reflects the amount of underlying muscle activated 37 and a dose response with an evoked force suggests that applying maximum tolerable intensity is optimal. 13 In the heavily sedated ICU patient, a predetermined strategy for setting and increasing intensity should be considered, as nerve excitability can diminish over the course of critical illness 38 requiring progressive increases in intensity levels 8, 25 and tolerance may be difficult to establish. Titrating to visible or palpable contraction is pragmatic, although applying current to pre-specified levels above threshold (the point at which minimum intensity evokes contraction) permits objective work level estimation. 39 The absolute number of contractions delivered during each treatment may also be an important factor in determining the Table 1 Characteristics of electrical muscle stimulation studies in the intensive care setting. optimal stimulus, although this has not been addressed in the ICU setting. As an early countermeasure to muscle atrophy, most ICU studies commenced treatment within 72 hours of ICU admission, 21, [23] [24] [25] although one study applied the first treatment within 26 hours of the diagnosis of sepsis. 8 The minimum duration of treatment that accompanied change in outcome was four days, 27 with a maximum of four weeks. 22 No treatment continued beyond the ICU setting, although ongoing research has extended EMS to hospital discharge. 32 Whether EMS is optimally delivered only during periods of immobility, is additionally effective or even necessary once patients start whole-body exercise has not yet been investigated. Extrapolating from healthy populations when given in isolation, the potential for EMS to evoke muscular adaptations which consistently translate into dynamic or functional gains is unclear, and applying treatment in addition to other rehabilitation techniques is probably more effective. 35 This may be because restricting EMS to agonist muscle groups without concurrent synergistic activation does not reflect normal functional movement. In the ICU, compelling evidence for early mobilisation means EMS should probably continue once other techniques have commenced. Surprisingly, only two ICU studies reported other mobilisation practice during EMS treatment periods, 8, 27 with only one detailing activities. 8 Combining EMS functionally with assisted passive or active cycling is the subject of a current ongoing trial. 28 The additional benefit of EMS to cycle ergometry will be evaluated in a single leg design, and alongside mass measures, fibrespecific changes through biopsy will be analysed. This important study will advance understanding of the mechanistic and adjunctive role of EMS in early ICU rehabilitation.
Review articles

Safety of EMS in ICU settings
Most rehabilitation procedures in critically ill patients have the potential to induce cardiorespiratory instability, although with response-dependant approaches, adverse event rates are typically low. 40 Physiological tolerance to EMS should be similarly monitored. The metabolic demand on muscle induced by EMS is greater than an equal-force voluntary contraction, 41 equating to a mild to moderate exercise response in healthy subjects with associated increases in heart rate and oxygen consumption. 42 In a preliminary safety study, sedated and mechanically ventilated patients, some on vasopressor support, received a 45-minute session of EMS to bilateral quadriceps and peroneus longus muscles. 26 Low frequency (45Hz), wide-pulsed EMS was delivered at intensities titrated to visible contraction. Artificial vascular occlusion of thenar microvasculature demonstrated the potential for EMS to increase systemic perfusion and muscle tissue oxygen consumption. Changes were transient and were accompanied by significant but clinically unimportant blood pressure and heart rate alterations. Ventilatory parameters remained unchanged. This study does not indicate at which point following admission patients received EMS although commencing treatment within 24 hours does not appear to induce cardiorespiratory compromise. 24 No premature termination of treatment due to physiological instability was reported by any other published ICU studies and most commenced treatment on potentially unstable patients, with a proportion on vasopressors, 8, 21, 25 and renal replacement therapy. 8, 25 Overall EMS appears safe in the critically ill.
The transition from sedation to wakening equally did not interrupt EMS when continued after awakening 23 and overall only two of 87 patients assigned to EMS reported pain, 25 the main limiting factor to effective treatment optimisation and delivery. 13 Only one study detailed strategy to prevent pain by employing wide pulsed, low frequency EMS, 8 although accurate identification of motor points pre-treatment reduces intensity requirements thereby limiting sensory discomfort. 43 This, along with analgesia and timing EMS outside sedation holds may help prevent pain. Elsewhere, frail hospitalised patients 44 and postoperative abdominal surgical patients 45, 46 have successfully tolerated EMS without pain. The impact on clinician workload of delivering EMS has not been investigated, and implementing single daily treatment EMS to a schedule in the ICU environment appears more successful, with patient inaccessibility the main limiting factor. 25
Effects of EMS on muscle wasting
All but one 23 of the published ICU RCTs incorporated some method of quantifying muscle mass, using either ultrasound (US) measurement of muscle thickness, 21, 22, 25 CT measurement of muscle volume 8 or limb circumference measurement. 24 No single surrogate measure of atrophy has been established in the ICU setting, although US reproducibly tracks muscle bulk on serial application in critically ill patients 8, 47 and correlates reasonably well with force in other patient groups. Anthropometric measurement represents fat-free mass poorly 47 and thus has less clinical utility in the ICU.
Irrespective of the mass measure used, quadriceps muscle bulk declined over the study period in three study cohorts, 8, 21, 22 with losses between 1% and 2.9% per day consistent with other reports. 47 Patients with multi-organ failure 5 had higher rates of muscle wasting. In the single-legged study (using the contralateral leg as control), EMS was ineffective in attenuating rate of muscle volume decline. 8 A trend towards greater loss in the stimulated limb could suggest that exercising muscle following acute onset of sepsis may in fact be detrimental. The 'septic muscle' is progressively less responsive to electrical stimulus, 25 and forcing repetitive contraction could hypothetically exacerbate muscle inflammation, perhaps delaying muscle recovery. 7 Early-onset muscle fatigue with EMS is well documented 48 and evidence that even moderate protocols can induce micro-injury has come to light fairly recently. 49 Taking indirect markers of muscle damage within a single-legged EMS study design however could not demonstrate injury. Two ongoing studies 28, 33 are also incorporating a biomarker analysis to assess muscle damage, although investigating direct histological changes are likely to be more informative. 28, 31 Conversely in less severely ill patients, muscle appears easier to influence; seven days of EMS attenuated rectus femoris thickness loss by as much as 42% compared to controls. 21 Notably, almost half the total number of contractions per treatment was delivered compared to the previous study. 8 Further along the illness trajectory, after 14 days of ICU stay and when the quadriceps had already significantly atrophied, EMS induced a small but significant hypertrophic response. 22 This followed an extended four-week stimulation period consistent with that seen in healthy muscle; despite demonstrable early improvements in muscle force, associated hypertrophic changes take considerably longer to realise. Illness severity, EMS parameters and the point along the critical illness trajectory at which EMS is commenced therefore may all be important factors in influencing outcome.
In otherwise healthy muscle, regular EMS reduces disuse atrophy 50 and has a small but significant attenuating influence on muscle volume loss in postoperative patients. 46 The exact mechanism by which EMS influences muscle mass is unclear, but the potential to induce an exercise response sufficient to overcome the marked depression in muscle protein synthesis that accompanies early critical illness 5 is thus far extrapolated from patients with similar catabolic conditions. 44, 46 Following major abdominal surgery, a four-day course of EMS was shown to reduce sarcoplasmic protein degradation compared to contralateral limb controls. 45 This duration of treatment had no impact on myosin thick filament loss, however, which is particularly marked in ICU myopathy. 51 An ongoing study 31 will examine this relationship further. Stimulating multiple limb and trunk muscles of ICU patients receiving MV, myosin thick filament content visualised on muscle biopsy and ubiquitin ligase activity (reflecting activation of the ubiquitinproteasome pathway which promotes atrophy) will be compared to sham controls. This will further the understanding of whether EMS has any true anabolic influence on protein degradation in critical illness.
Effects of EMS on muscle strength
Muscle strength is dependent on force generation for a given amount of muscle mass and total muscle mass. This suggests muscle mass reductions sustained during early critical illness should significantly impact strength at patient awakening. However, dramatic atrophy can occur without concomitant reduction in muscle-specific force generation, 7,52 and EMSevoked strength improvements can equally take place without concurrent alterations in muscle mass. 34 Only one ICU study measured both parameters following daily EMS continuing to ICU discharge. 25 Despite the difficulties of volitional strength measurement in the ICU, biceps strength, assessed by the ordinal manual muscle Medical Research Council (MRC) test, increased by one point, consistent with attaining antigravity strength. US thickness however remained unchanged. Until the relationship between quantified muscle loss and subsequent strength is established the best clinical endpoint to examine EMS efficacy remains uncertain.
Two studies examined muscle strength in mixed and septic patient ICU cohorts 23, 25 following at least 13 days of EMS. MRC strength scoring was performed at awakening in directly stimulated muscles, 25 and compared with non-stimulated upper and lower limb muscles. 23, 25 No detail on other physical activity or mobilisation practice was presented. Although reduced cognition precluded assessment of 23% of patients in one cohort, 23 individual EMS-targeted muscles were significantly stronger than controls in both studies, and there was some carryover to wrist and ankle flexors. 23, 29 Based on a MRC cut-off score, 3 an overall reduction in ICU-acquired weakness (ICU-AW) incidence was observed with EMS (OR=0.22 (0.05-1.02). 23 Defined by this criteria, ICU-AW was an independent predictor of prolonged MV 6 and an accompanying significant reduction in weaning days was also seen in the EMS group. This implies lower limb stimulation had some carryover to respiratory musculature, although without quantitative assessment of respiratory dynamics, this is conjecture. Moreover, improved lower limb power could have promoted earlier achievement of functional milestones and hence global muscle strength, which in turn facilitated earlier weaning, although this association was not investigated and neither group' s mobility data nor functional assessment was presented. MV liberation is an important issue for patients, 53 and the role of EMS in achieving this outcome requires further investigation.
Future research
Although preliminary work suggested a potential benefit from EMS in selected ICU subgroups, with acceptable tolerance and safety, there is enormous scope for mechanistic evaluation of EMS in acute critical illness-associated myopathy, and subsequent phase II functional outcome research. Stratifying patient subgroups, defining optimal EMS protocols and their role in adjunct or isolation, and the cost-effectiveness of EMS delivery will all be necessary before this treatment is widely used by ICU clinicians. Two ongoing phase II studies 28, 31 analysing biopsies from stimulated muscle following superimposed passive exercise 28 and extensive limb and trunk stimulation 31 may show how EMS works at bimolecular and cellular level, in septic and heterogeneous patient cohorts. Furthermore, EMS in addition to standardised usual physiotherapy care 30, 33 compared to sham control should give some insight as to whether EMS impacts short-term functional outcomes and perceived health status 33 compared to standard care alone. Reflecting the lack of consensus on core outcome measures for the ICU population, only two studies include validated ICU-specific measures; 28, 30 the remaining use a range of functional measures. However in conjunction with manual muscle strength and morphology data, 28, 32, 33 collectively they may help define the relationship between specific acquired muscle deficits and mobility problems in the short term. Addressing the patient experience of EMS would also give insight into its acceptability, equally important if it is to be considered a viable treatment option.
Conclusion
EMS has been used clinically for many years to prevent muscle atrophy and improve strength and has been introduced recently to ICU patients receiving MV as a countermeasure for muscle wasting and weakness. Preliminary data suggests EMS is safe and may have some benefit in attenuating muscle atrophy and improving strength in this population, although the consequence to functional outcomes has not been explored. Further research may help establish the underlying mechanism by which EMS could prevent ICU-AW and determine its role in intensive care rehabilitation.
